Novelix Pharmaceuticals Ltd (NOVELIX)

Loading page…

Novelix Pharmaceuticals Ltd (NOVELIX) · mywealthgrid

About

Novelix Pharmaceuticals Ltd is a small-cap healthcare technology company (₹175.21 Cr market cap) specializing in Healthcare Research, Analytics & Technology. Latest quarterly revenue reached ₹20.86 Cr (Mar 2025), up sharply from ₹5.3 Cr in Dec 2024, indicating rapid expansion. With minimal debt (D/E 0.02) and a 74.55% one-year stock return, the company shows strong investor interest despite ongoing profitability challenges.

Face value: ₹10

Market cap

₹167 Cr

P/E

—

P/B

22.6×

Dividend yield

ROE

-28.5%

ROCE

-28.1%

Debt / equity

0.02

OPM

-29.9%

EPS (TTM)

₹-0.8

Book value

₹3.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Profitability gap: annual OPM -29.85% and ROE -28.47% contrast with recent positive quarterly results, raising questions about whether the business model is truly sustainable at scale

Revenue volatility: quarterly revenues swing from ₹0.43 Cr (Dec 2022) to ₹20.86 Cr (Mar 2025), making it difficult to assess organic growth or forecast future performance

Margin compression under growth: operating margin fell from 5.56% (Sep 2024) to 1.1% (Mar 2025) even as revenue quadrupled, indicating unit economics may deteriorate at scale

Valuation at peak: stock trading at ₹73.31 near 52-week high of ₹88.8 with 74.55% annual return already built in—verify whether current risk/reward remains attractive

Generated analysis · source review pending

Growth drivers

Revenue traction: ₹20.86 Cr in Mar 2025 vs ₹5.3 Cr in Dec 2024 shows 4x quarterly growth; verify whether this reflects new customers, product expansion, or one-time deals

Healthcare analytics sector: positioned in Healthcare Research, Analytics & Technology; verify India's healthcare data analytics adoption trends and addressable market size

Low leverage: D/E 0.02 provides balance-sheet flexibility to invest in growth without debt constraints; verify capital requirements to scale the business

Emerging profitability: Sep 2024 through Mar 2025 show positive net profit after prior-year losses; verify which segments are profitable and whether this trend sustains

Generated analysis · source review pending

1,179 historical price candles were omitted because the exchange source has not been verified.

₹70.0-0.1%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of -41.6% (3-yr avg)
−Revenue shrank over the last 3 years (-97.5% a year)
−Trading at 22.6× book value
−Promoter holding fell 2.2 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

25/100

Business quality: 25
Growth: 0
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2016	Mar 2017	Mar 2021	Mar 2022
	5,71,593	9,18,636	9	9
COGS	-642	-25,117	7	8
Gross profit	—	—	2	0
	5,17,149	9,17,124	6	3
Operating profit (EBITDA)	55,085	26,628	-4	-3
OPM %	9.6%	2.9%	-41.1%	-29.9%
Depreciation	35,075	19,103	0	0
Interest	61	5,018	0	0
	13,379	16,863	0	1
Profit before tax	24,157	19,370	-4	-2
Tax	11,202	16,029	0	-0
Tax %	46.4%	82.8%	0.3%	-0.5%
	12,955	3,341	-4	-2
PAT margin %	2.3%	0.4%	-40.7%	-23.6%
EPS (₹)	0.1	-0	—	—
EPS adjusted (₹)	—	—	-4.6	-2.5
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2021	Annual report for Mar 2022

₹ Cr	Mar 2021	Mar 2022
Equity capital	8	8
Reserves	-1	-1
Minority interest	1	0
	0	0
	2	1
Total equity & liabilities	10	9
	2	0
CWIP	—	—
Investments	0	2
	8	6
Total assets	10	9

₹ Cr	Mar 2016	Mar 2017	Mar 2021	Mar 2022
	2	-1	2	2
	-2	1	0	-1
	0	0	-1	0
Net cash flow	0	-0	1	1
Free cash flow	2	-1	2	-0
CFO / Operating profit %	0%	-0%	—	—

Compounded sales growth

7 years: —
5 years: —
3 years: -98%
1 year: -7%

Return on equity

7 years: —
5 years: —
3 years: —
Last year: -26%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2016	Mar 2017	Mar 2021	Mar 2022
Margins
Gross margin %	—	—	24.2%	4.3%
EBITDA margin %	9.6%	2.9%	-41.1%	-29.9%
EBIT margin %	3.5%	0.8%	-43.4%	-31%
PAT margin %	2.3%	0.4%	-40.7%	-23.6%
Working capital
Receivable days	—	—	55	52
Inventory days	—	—	48	44
Payable days	—	—	112	39
NWC days	—	—	-9	57
Leverage
Current ratio	—	—	3.38	5.59
Debt to EBITDA	—	—	—	—
Debt to equity	—	—	0	0.02
Interest coverage	544.3	4.9	-61	—
Asset turnover	—	—	0.97	0.99
Return ratios
Return on assets %	—	—	-39.3%	-23.2%
Return on capital employed %	—	—	-49.5%	-28.1%
Return on equity %	—	—	-54.8%	-27.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	66.92%	66.92%	66.92%	66.54%	66.56%	66.56%	66.56%	52.75%	53.33%	51.98%	49.43%	50.57%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	33.08%	33.08%	33.08%	33.46%	33.44%	33.44%	33.44%	47.25%	46.67%	48.02%	50.57%	49.43%
No. of shareholders	—	—	—	—	—	—	—	—	2,697	2,994	2,975	3,118

Promoter holding down 16.35 percentage points since Sep 2023.

3 deals · 12 Jan 2022 – 3 Jul 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
3 Jul 2025	MEDO CAPITAL SERVICES PRIVATE LIMITED	Bulk	BSE	Sell	1,25,000	₹43.29	₹0.54 Cr
12 Jan 2022	INDUS CAPITAL PRIVATE LIMITED	Bulk	BSE	Buy	57,133	₹8.55	₹0.05 Cr
12 Jan 2022	BEKAE PROPERTIES PRIVATE LIMITED	Bulk	BSE	Sell	57,133	₹8.55	₹0.05 Cr

1–3 of 3

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. VENKATESHWARLU PULLURUExecutive Director
Mr. GNANA PRAKASH GATTUNon-Executive - Non Independent Director
Ms. SRIDEVI BELIDENon-Executive - Non Independent Director
Mr. JANARDHAN DAS KABRANon-Executive - Independent Director
Vani MandaChief Financial Officer
Mr. LAKSHMAN SAMALANon-Executive - Independent Director
Mrs. MAYURI BAIDYANon-Executive - Independent Director
Ms. Bhoomik ChoudharyChief Financial Officer
Ms. Nishita KalantriCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Novelix Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results13 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

8 announcementsExport CSV

1 Oct 2026, 7:17 pmAGM/EGM

Shareholders Meeting- Voting Results

AGM PDF

Loading announcements…

Ratio	Mar 2016	Mar 2017	Mar 2021	Mar 2022
Margins
Gross margin %	—	—	24.2%	4.3%
EBITDA margin %	9.6%	2.9%	-41.1%	-29.9%
EBIT margin %	3.5%	0.8%	-43.4%	-31%
PAT margin %	2.3%	0.4%	-40.7%	-23.6%
Working capital
Receivable days	—	—	55	52
Inventory days	—	—	48	44
Payable days	—	—	112	39
NWC days	—	—	-9	57
Leverage
Current ratio	—	—	3.38	5.59
Debt to EBITDA	—	—	—	—
Debt to equity	—	—	0	0.02
Interest coverage	544.3	4.9	-61	—
Asset turnover	—	—	0.97	0.99
Return ratios
Return on assets %	—	—	-39.3%	-23.2%
Return on capital employed %	—	—	-49.5%	-28.1%
Return on equity %	—	—	-54.8%	-27.4%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Syngene International LimitedSYNGENESYNGENE	₹14,586 Cr	₹14,595 Cr	₹3,600 Cr	₹803 Cr	24.6%	₹221 Cr	8.5%	9.8%	6.6%	-32
Indegene LimitedINDGNINDGN	₹14,303 Cr	₹14,303 Cr	₹3,813 Cr	₹638 Cr	17.6%	₹401 Cr	11.4%	17.9%	13.9%	79
Suven Life Sciences LimitedSUVENSUVEN	₹8,139 Cr	₹8,139 Cr	₹9 Cr	₹-366 Cr	—	₹-352 Cr	—	-78.4%	-78.8%	72
Vimta Labs LimitedVIMTALABSVIMTALABS	₹2,612 Cr	₹2,631 Cr	₹336 Cr	₹112 Cr	27.3%	₹61 Cr	12.9%	17.4%	13.6%	179
Bilcare LimitedBIBI	₹227 Cr	₹896 Cr	₹788 Cr	₹45 Cr	5.7%	₹-29 Cr	-7.1%	1.5%	-6%	78
Take Solutions LimitedTAKETAKE	₹187 Cr	₹187 Cr	₹85 Cr	₹-2 Cr	-3.5%	₹13 Cr	20%	18.5%	42.1%	-7
Jeevan Scientific Technology LtdJSTLJSTL	₹169 Cr	₹186 Cr	₹62 Cr	₹10 Cr	16%	₹0 Cr	1.7%	5.4%	1.7%	-109
Novelix Pharmaceuticals LtdNOVELIXNOVELIX	₹167 Cr	₹167 Cr	₹9 Cr	₹-3 Cr	-29.9%	₹-2 Cr	-23.6%	-28.1%	-28.5%	57
Globalspace Technologies LtdGSTLGSTL	₹103 Cr	—	₹25 Cr	₹11 Cr	5.9%	₹7 Cr	-1.4%	—	—	—
Adeshwar Meditex LtdADESHWARADESHWAR	₹23 Cr	—	₹56 Cr	₹3 Cr	4.9%	₹1 Cr	2.3%	—	—	—
Vanta Bioscience LtdVANTABIOVANTABIO	₹15 Cr	—	₹2 Cr	₹1 Cr	56.6%	₹0 Cr	6%	—	—	—

Date	Category	Subject	Filing
1 Oct 2026, 7:17 pm	AGM/EGM AGM	Shareholders Meeting- Voting Results	PDF
1 Oct 2026, 7:16 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
30 Sept 2026, 6:19 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
30 Sept 2026, 4:02 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
9 Sept 2026, 8:25 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
7 Sept 2026, 10:22 pm	Company Update General	Announcement Under Regulation 30 (LODR)- Letter Of Annual Report & AGM Notice Weblink	PDF
7 Sept 2026, 10:19 pm	AGM/EGM AGM	Shareholders Meeting- Notice Of Annual General Meeting To Be Held On Wednesday, 30Th September, 2026.	PDF
7 Sept 2026, 10:16 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF

Novelix Pharmaceuticals Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1